BioCentury | Dec 18, 2020
Management Tracks

Rim named CEO of Samsung Biologics as Sarepta unveils promotions; plus Coughlin, Iovance, SpringWorks and NodThera

...Ltd. as CMO and CFO, respectively. Johns was CMO and EVP of medical and scientific affairs at Syntimmune Inc. Dorton...
...pyrin domain containing 3 Danielle Golovin Sarepta Therapeutics Inc. Iovance Biotherapeutics Inc. Gritstone Oncology Inc. SpringWorks Therapeutics Inc. NodThera Ltd. Repare Therapeutics Inc. Syntimmune Inc. NLR...
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

...to deals for clinical-stage companies. Its takeouts of Achillion Pharmaceuticals Inc. last year, and of Syntimmune Inc....
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

...strategy to maintain that position includes adding an FCRN inhibitor through its 2018 takeout of Syntimmune Inc....
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...bought two companies last year, paying $400 million up front for rare autoimmune disease company Syntimmune Inc....
BioCentury | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

...company Cadent Therapeutics inc. (Cambridge, Mass.) hired John McBride as CFO. He was CFO of Syntimmune Inc....
BioCentury | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

...antibody company in 1992. Kress served as president and CEO of rare autoimmune disease company Syntimmune Inc....
BioCentury | Jun 19, 2019
Financial News

Coenzyme A company Comet debuts with $28.5M series A

...Led by former Syntimmune CEO David de Graaf, Comet launched Wednesday with $28.5 million in series...
...as fatty acid synthesis, regulation of gene expression and energy production. de Graaf’s previous company, Syntimmune Inc....
...for $400 million up front and a potential $800 million in milestones last year (see “Syntimmune...
BioCentury | May 6, 2019
Company News

Management tracks: Batu, Halozyme, FOG

...a director of the red blood cell-based therapeutic company. Kress was CEO and chairman of Syntimmune Inc....
BioCentury | Mar 20, 2019
Company News

Alexion augmenting pipeline with Zealand, Affibody deals

...disclose indications this year. Last year, Alexion gained FCRN-targeting mAb SYNT001 via its takeout of Syntimmune Inc....
...hemolytic anemia and a Phase Ib/II trial to treat pemphigus vulgaris or pemphigus foliaceus (see "Syntimmune...
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...Mass.) hired Mario Saltarelli as CMO, a new position. He was EVP and CMO of Syntimmune Inc....
Items per page:
1 - 10 of 24
BioCentury | Dec 18, 2020
Management Tracks

Rim named CEO of Samsung Biologics as Sarepta unveils promotions; plus Coughlin, Iovance, SpringWorks and NodThera

...Ltd. as CMO and CFO, respectively. Johns was CMO and EVP of medical and scientific affairs at Syntimmune Inc. Dorton...
...pyrin domain containing 3 Danielle Golovin Sarepta Therapeutics Inc. Iovance Biotherapeutics Inc. Gritstone Oncology Inc. SpringWorks Therapeutics Inc. NodThera Ltd. Repare Therapeutics Inc. Syntimmune Inc. NLR...
BioCentury | May 5, 2020
Deals

Alexion sees opportunity in slow-selling Andexxa, buys Portola for $1.4B

...to deals for clinical-stage companies. Its takeouts of Achillion Pharmaceuticals Inc. last year, and of Syntimmune Inc....
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

...strategy to maintain that position includes adding an FCRN inhibitor through its 2018 takeout of Syntimmune Inc....
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...bought two companies last year, paying $400 million up front for rare autoimmune disease company Syntimmune Inc....
BioCentury | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

...company Cadent Therapeutics inc. (Cambridge, Mass.) hired John McBride as CFO. He was CFO of Syntimmune Inc....
BioCentury | Jun 24, 2019
Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

...antibody company in 1992. Kress served as president and CEO of rare autoimmune disease company Syntimmune Inc....
BioCentury | Jun 19, 2019
Financial News

Coenzyme A company Comet debuts with $28.5M series A

...Led by former Syntimmune CEO David de Graaf, Comet launched Wednesday with $28.5 million in series...
...as fatty acid synthesis, regulation of gene expression and energy production. de Graaf’s previous company, Syntimmune Inc....
...for $400 million up front and a potential $800 million in milestones last year (see “Syntimmune...
BioCentury | May 6, 2019
Company News

Management tracks: Batu, Halozyme, FOG

...a director of the red blood cell-based therapeutic company. Kress was CEO and chairman of Syntimmune Inc....
BioCentury | Mar 20, 2019
Company News

Alexion augmenting pipeline with Zealand, Affibody deals

...disclose indications this year. Last year, Alexion gained FCRN-targeting mAb SYNT001 via its takeout of Syntimmune Inc....
...hemolytic anemia and a Phase Ib/II trial to treat pemphigus vulgaris or pemphigus foliaceus (see "Syntimmune...
BioCentury | Mar 19, 2019
Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

...Mass.) hired Mario Saltarelli as CMO, a new position. He was EVP and CMO of Syntimmune Inc....
Items per page:
1 - 10 of 24